Spectral Medical Inc (TSE:EDT) Director Kevin Arnold Giese acquired 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of C$0.75 per share, for a total transaction of C$37,500.00. Following the purchase, the director now directly owns 3,426,336 shares in the company, valued at approximately C$2,569,752.
Shares of Spectral Medical stock opened at C$0.75 on Friday. The company has a market capitalization of $155.81 million and a PE ratio of -57.69. Spectral Medical Inc has a 12 month low of C$0.30 and a 12 month high of C$0.85. The company has a current ratio of 4.24, a quick ratio of 3.64 and a debt-to-equity ratio of 21.26. The stock’s fifty day simple moving average is C$0.75 and its 200 day simple moving average is C$0.55.
Spectral Medical (TSE:EDT) last issued its quarterly earnings data on Thursday, November 14th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.53 million during the quarter. Analysts predict that Spectral Medical Inc will post -0.06 EPS for the current fiscal year.
About Spectral Medical
Spectral Medical Inc focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan.
Further Reading: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.